Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Has everyone seen (I saw at Fidelity) the language for shareholders to vote on?
Seems to be enabling a possible reverse split, although they call it a "consolidation." I presume it is for uplistng.
"BE IT RESOLVED AS A SPECIAL RESOLUTION OF THE SHAREHOLDERS OF THE CORPORATION THAT:
(1) THE ARTICLES OF THE CORPORATION BE AMENDED TO CONSOLIDATE THE ISSUED AND OUTSTANDING COMMON SHARES OF THE CORPORATION (“COMMON SHARES”), ON THE BASIS OF A CONSOLIDATION RATIO TO BE SELECTED BY THE CORPORATION’S BOARD OF DIRECTORS, IN ITS SOLE DISCRETION, PROVIDED THAT (A) THE RATIO MAY BE NO SMALLER THAN ONE POST-CONSOLIDATION SHARE FOR EVERY FIVE PRE-CONSOLIDATION SHARES AND NO LARGER THAN ONE POST-CONSOLIDATION SHARE FOR EVERY 25 PRE-CONSOLIDATION SHARES, AND (B) THE NUMBER OF PRE-CONSOLIDATION SHARES IN THE RATIO MUST BE A WHOLE NUMBER OF COMMON SHARES;
(2) NO FRACTIONAL COMMON SHARES SHALL BE ISSUED IN CONNECTION WITH THE CONSOLIDATION AND, IN THE EVENT THAT A SHAREHOLDER WOULD OTHERWISE BE ENTITLED TO RECEIVE A FRACTIONAL SHARE UPON CONSOLIDATION, SUCH SHAREHOLDER SHALL HAVE SUCH FRACTIONAL SHARE CANCELLED;
(3) THE EFFECTIVE DATE OF SUCH CONSOLIDATION SHALL BE THE DATE SHOWN IN THE CERTIFICATE OF AMENDMENT ISSUED BY THE DIRECTOR APPOINTED UNDER THE CANADA BUSINESS CORPORATIONS ACT (THE “CBCA”) OR SUCH OTHER DATE INDICATED IN THE ARTICLES OF AMENDMENT;
(4) ANY ONE DIRECTOR OR OFFICER OF THE CORPORATION IS HEREBY AUTHORIZED TO EXECUTE AND DELIVER, FOR AND ON BEHALF OF THE CORPORATION, ALL SUCH DOCUMENTS AND TO DO ALL SUCH OTHER ACTS AND THINGS AS MAY BE CONSIDERED NECESSARY OR DESIRABLE TO GIVE EFFECT TO THIS RESOLUTION INCLUDING, WITHOUT LIMITATION, THE DELIVERY OF ARTICLES OF AMENDMENT IN THE PRESCRIBED FORM TO THE DIRECTOR APPOINTED UNDER THE CBCA; AND
(5) NOTWITHSTANDING THE FOREGOING, THE DIRECTORS OF THE CORPORATION ARE HEREBY AUTHORIZED, WITHOUT FURTHER APPROVAL OF THE SHAREHOLDERS OF THE CORPORATION, TO REVOKE THIS SPECIAL RESOLUTION AT ANY TIME PRIOR TO THE ENDORSEMENT BY THE DIRECTOR APPOINTED UNDER THE CBCA OF A CERTIFICATE OF AMENDMENT."
Bob, Can you point us in the direction of a particular SEC filing by MNOV which represents an ATM issuance of shares?
If only he had said that (about the Trimesta trial) at the time.
Well, you could try to assemble which patents MARA acquires in each portfolio and then try to follow through with which patents survive challenge by the entities MARA has sued. Then you could see which ones were included within a successful settlement and do some calculations. There would be a lot of delays between the different steps, tho. Also, if MARA is acquiring a whole portfolio of patents, I expect Doug calculated different values for each patent.
It sounds like a lot of potential work and then it is still hard to know whether it was the "004 patent" or the "985 patent" which caused the company we sued to settle.
I think I'll just trust Doug and company, as their financial interest is pretty well aligned with ours.
GL and LLAP
A "success ratio" also would be saying that everything is apples, while the prospective value of each piece of litigation, hearing, trial, etc. can be apples to oranges and dramatically different.
Drano did not bail. Spoke with him today.
Thank you for Carl's thoughts. I felt the news, while "important" does not remotely translate to an FDA approval. This is one stock I am willing to do my slow-dance version of swing trading, although most of our shares were untouched.
Drano and I are periodically in touch. He has been really busy at work.
George, Happy I did sell some yesterday, and part of me wishes my sell orders at higher prices had also gone off.
OTOH, it looks as if the price is slowly decaying toward what it was before the announcements yesterday and that I will be reacquiring those shares I sold yesterday, but at a lower price and reinvesting the profit in more shares.
I do not want to be out of MNOV.
George, Agreed. I've always bought more shares (than I had before) when I repurchase MNOV. LLAP
LOL. Any accurate indicator can guide investors.
Perhaps. Do you think it will break $4 on the way back down? I don't think it will quite go back to yesterday's price ... but who knows.
Sold some MNOV this morning at $5.35. You may now expect it to top $6 this afternoon.
Thank you for that report!
Another "sale" at Caskers. Jefferson's Reserve at $60.
https://www.caskers.com/jefferson-s-reserve-very-old-straight-bourbon-whiskey-2630/
Crudeoil, Happy to receive the PM but can't respond by PM until happy hour tomorrow.
The question is generally out of curiosity to see how you are approaching this. My guess is that you swing trade and probably prefer to be back in cash by closing on Friday. Nothing wrong with trading and I have friends who primarily do trading. Minding and I both have been known to sell portions of our MNOV shares at what seem to be peaks.
EDIT: But Minding can correct me if he has never sold!
Crudeoil, So when did you get into MNOV and what is you price and timeline objective? How long do you hold your stocks?
George, Your friend has a good thought process.
Thank you. I'm frankly delighted at the jump to above $5.
Agreed
Yes, Premarket looks spectacular. Only question is whether is rises a bit more or does it settle back?
Both items of news today are good for MNOV.
FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis
MediciNova, Inc.
LA JOLLA, Calif., April 16, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for MN-001 (tipelukast) for the treatment of patients with nonalcoholic steatohepatitis (NASH) with fibrosis. Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening diseases and demonstrate the potential to address unmet medical needs for such diseases. An important feature of the FDA's Fast Track program is that it emphasizes frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval.
In January 2015, MediciNova announced an open Investigational New Drug (IND) application for MN-001 in NASH. Importantly, due to safety data from previous clinical studies of MN-001, FDA has agreed that MediciNova may proceed with a Phase 2 study as the first clinical study of MN-001 in NASH.
LA JOLLA, Calif., April 16, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that the Tokyo Stock Exchange (TSE) has announced a new rule affecting the trading of dual-listed stocks on the Tokyo Stock Exchange, including the stock of MediciNova. Under the old rule, the TSE had used the previous day's closing price of MediciNova's stock on the TSE as the base price to determine the daily limit of the stock price movement on the TSE (also known as the "circuit breaker" rule). Under the new rule that will become effective on April 20, 2015, if (1) the difference between the previous day's closing price of MediciNova's stock on NASDAQ converted to Japanese yen and the previous day's closing price of MediciNova's stock on the TSE ("the price divergence") is greater than the daily limit of the stock price movement on the TSE and (2) the price divergence is greater than 20%, then the TSE will use the previous day's closing price of MediciNova's stock on NASDAQ converted to Japanese yen as the base price to determine the daily limit of the stock price movement on the TSE.
Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased with this rule change as our stock price movements on NASDAQ and TSE should now occur in a more synchronized fashion than has occurred previously."
Max, FWIW, they dropped their fictitious price to 99.99.
Sale at Caskers on Jeff's Ocean, $99.99:
https://www.caskers.com/jefferson-s-ocean-aged-at-sea-kentucky-straight-bourbon/?utm_source=Caskers+Members&utm_campaign=bde8823ea0-Ocean&utm_medium=email&utm_term=0_9cb813dba9-bde8823ea0-21865545
Edit: I can't tell which voyage this is but presume the latest.
I realize it may be "dead money" but I am continuing to hold.
No argument there, but down and up in one day is a bit much
That was not Zacks last time. Not that I'm defending Zacks competence, mind you.
Fidelity shows the following upgrades and one downgrade today:
Zacks Investment Research, Inc. upgrades MARATHON PATENT GROUP INC from SELL to HOLD.
Investars Analyst Actions - private – 12:07 PM ET 04/10/2015
ValuEngine upgrades MARATHON PATENT GROUP INC from HOLD to BUY.
Investars Analyst Actions - public – 7:12 AM ET 04/10/2015
Zacks Investment Research, Inc. downgrades MARATHON PATENT GROUP INC from HOLD to SELL.
Investars Analyst Actions - private – 7:10 AM ET 04/10/2015
Just how Zacks can downgrade and then reverse the action in one day is beyond me.
We'll build a statue to you as our thanks!
Fun, Sometimes it's good to get away from the touristy stuff. My first time to London, the wife and I spent lots of time consuming champagne, chocolate and raspberries. Your cousin could probably have you zip (sip?) by there for lunch!
Max, from google translate:
Discover Umbria!
Ciao tutti treats on Gozio Amaretto
February 4, 2015 Ciao tutti 5 years 1 comment
We were allowed some time ago tasting Gozio Amaretto, now it's your turn. We can make happy five readers with a bottle of Amaretto Gozio.
The amaretto of Gozio is a mix of alcohol, burnt sugar and essence of the best quality bitter almonds. Unlike many other famous amaretto (which then also officially not allowed to be called), Gozio Amaretto on craft, naturally produced and Almond protagonist. No peach pits or other 'nepamandelen' for Italian gold.
And I left out:
Especially for Valentine we share one more recipe with amaretto, the Amaretto Cranberry Kiss. For two cocktails you need: 250 ml cranberry juice, 120 ml of vodka, 60ml amaretto, half tablespoon freshly squeezed orange juice and ice. Mix all liquids, they shake with ice and serve cocktails in pretty glasses, garnished with a slice of orange peel. Salute!
Funman will have to check it out when he is there!
Don't pay anything! LOL.
SLC would be happy to provide the same service much more effectively.
I think they can use a bot to assemble the data, then sell to the suckers willing to pay the price. There should be very little cost of production and huge margins. Any stock, even a "penny" like CTIX, which has a large number of holders and posters has a large number of possible buyers.
OTOH, a large cap like GE would have far more holders and lots more available public info, but the comparative lack of information on a stock like CTIX probably means more sales.
Why not go to the vendor's site and see what other reports they offer?
I would not be surprised if it's simply an on-demand service, like I use in doing a background investigation of an individual entrepreneur when I'm considering an angel investment. Lots of crap pulled from public sources. Sometimes gems I was not aware of. Sometimes just junk.
ETL, These reports do not have access to non-public information. Typically they simply aggregate what is known and available.
We have better report sources in SLCImmuno and KarinCA.
Max,
If there actually were to be a shortage, prices of lower end products will rise. With the same or similar price for a cheap bourbon or a premium bourbon, that means we sell ours easily. Oversimplification I know, as all prices would rise, but a better situation for a seller than a glut. Trey has a knack for sourcing, so I'm not worried.
DM, That's all tautological reasoning.
As long as I have a spare bottle of Jefferson's - any Jefferson's - I'll be ok. May not share but I'll be ok.
Article: Is the US Running Out Of Bourbon
http://www.eater.com/drinks/2015/4/8/8367315/is-there-really-a-bourbon-shortage
Well, I would prefer it uplist through organic growth, but reaching a consistent level of $4-5 that way will take a year or two. Uplist through a 1/4 or 1/5 reverse split is certainly a possibility. While it would subject the stock to more short selling pressure, it has already been a football, so there might be little downside to a r/s.